Cipla is reportedly planning to enter the branded formulation market in China in coming quarters either by acquiring a company or collaborating with a local partner. The company is planning to focus on respiratory therapeutics in the country.
Cipla’s proposed entry into China’s branded respiratory segment is in line with its pursuit to build a global respiratory franchise. The segment alone contributed about one-fifth to Cipla’s sales of Rs 14,630 crore in FY17.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.70 |
| Dr. Reddys Lab | 1224.40 |
| Cipla | 1235.05 |
| Zydus Lifesciences | 930.00 |
| Lupin | 2315.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: